Synonym
Quinine hydrobromide; CCRIS5753; CCRIS-5753 CCRIS 5753
IUPAC/Chemical Name
Cinchonan-9-ol, 6'-methoxy-, monohydrobromide, (8-alpha,9R)- (9CI)
InChi Key
HDZGBIRSORQVNB-DSXUQNDKSA-N
InChi Code
InChI=1S/C20H24N2O2.BrH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1H/t13-,14-,19-,20+;/m0./s1
SMILES Code
C=C[C@@H](C[N@@]1CC2)[C@@H]2C[C@H]1[C@H](O)C3=CC=NC4=CC=C(OC)C=C34.[H]Br
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
405.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: THOMSON W. Zur Charakteristik der Handelssorten von Chininhydrobromide und -hydrochlorid [Characteristics of commercial preparations of quinine hydrobromide and quinine hydrochloride]. Pharm Zentralhalle Dtschl. 1954 Jul;93(7):261-6. German. PMID: 13204151.
2: Sideropoulos AS, Specht SM, Jones MT. Feasibility of testing DNA repair inhibitors for mutagenicity by a simple method. Mutat Res. 1980 Apr;74(2):95-105. doi: 10.1016/0165-1161(80)90235-6. PMID: 6990235.
3: Zhang L, Wang R, Zhang Y, Yu Y. Application of high performance capillary electrophoresis on toxic alkaloids analysis. J Sep Sci. 2007 Jun;30(9):1357-63. doi: 10.1002/jssc.200600363. PMID: 17623479.
4: ROSSANDA M. Ricerche cliniche e sperimentali sull'associazione di canfosulfonato d'ammonio e bromidrato di chinina [Clinical and experimental study of the association of ammonium camphorsulfonate and quinine hydrobromide]. Arch Farmacol Sper Sci Affin. 1953 May-Jun;81(5-6):128-31. Italian. PMID: 14377785.
5: Rogers L I M S. Pernicious Malignant Tertian Malaria Successfully Treated by Quinine Acid Hydrobromide Intravenously and the Failure of "Splenox" in Benign Tertian Malaria. Ind Med Gaz. 1917 Nov;52(11):385-386. PMID: 29007628; PMCID: PMC5176450.
6: Hensler JG, Ladenheim EE, Lyons WE. Ethanol consumption and serotonin-1A (5-HT1A) receptor function in heterozygous BDNF (+/-) mice. J Neurochem. 2003 Jun;85(5):1139-47. doi: 10.1046/j.1471-4159.2003.01748.x. PMID: 12753073.
7: Jansen PH, Veenhuizen KC, Wesseling AI, de Boo T, Verbeek AL. Randomised controlled trial of hydroquinine in muscle cramps. Lancet. 1997 Feb 22;349(9051):528-32. doi: 10.1016/s0140-6736(97)80085-2. PMID: 9048790.
8: Pradines B, Ramiandrasoa F, Basco LK, Bricard L, Kunesch G, Le Bras J. In vitro activities of novel catecholate siderophores against Plasmodium falciparum. Antimicrob Agents Chemother. 1996 Sep;40(9):2094-8. doi: 10.1128/AAC.40.9.2094. PMID: 8878587; PMCID: PMC163479.
9: van Kan HJ, Jansen PH, Tuinte C, Smits P, Verbeek AL. Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. Eur J Clin Pharmacol. 2000 Jun;56(3):263-7. doi: 10.1007/s002280000128. PMID: 10952483.
